In October, 2023 Lung Therapeutics was acquired by Aileron Therapeutics. Aileron is now a pharmaceutical company targeting niche, orphan drug indications for lung injury and disease, with an emphasis on fibrosis. The company is developing a proprietary pipeline of therapeutics with the potential to greatly improve outcomes over currently available treatments. The company’s lead clinical programs include LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE). For more information about the company, please visit https://aileronrx.com
View Top Employees from Lung Therapeutics, Inc.Website | https://aileronrx.com |
Revenue | $2 million |
Funding | $36.1 million |
Employees | 20 (20 on RocketReach) |
Founded | 2013 |
Address | 3801 S Capitol of Tx Hwy Ste 330, Austin, Texas 78704, US |
Phone | (737) 802-1979 |
Technologies |
HTML,
Twitter,
Google Analytics
+10 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Health Care, Business Services, Medical, Therapeutics |
Web Rank | 9 Million |
Keywords | Lung Therapeutics, Loculated Pleural Effusion, Loculated Effusion, Lti-01, Lung Theraptuetics |
Competitors | HARBOUR BIOMED, Neuren Pharmaceuticals, NeuroHealing Pharmaceuticals, Inc., Retrotope, Inc., Rexahn Pharmaceuticals |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 32 Companies, NAICS Code 3254 Companies, NAICS Code 32541 Companies, NAICS Code 325 Companies |
Looking for a particular Lung Therapeutics, Inc. employee's phone or email?
The Lung Therapeutics, Inc. annual revenue was $2 million in 2024.
Matt Karpen is the Vice President, CMC of Lung Therapeutics, Inc..
20 people are employed at Lung Therapeutics, Inc..
Lung Therapeutics, Inc. is based in Austin, Texas.
The NAICS codes for Lung Therapeutics, Inc. are [32, 3254, 32541, 325].
The SIC codes for Lung Therapeutics, Inc. are [28, 283].